142 related articles for article (PubMed ID: 29370903)
1. LKB1 inactivation occurs in a subset of esophageal adenocarcinomas and is sufficient to drive tumor cell proliferation.
Whitsett TG; Mittal SK; Eschbacher JM; Carson VM; Smith MA; Bremner RM; Inge LJ
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1891-1899. PubMed ID: 29370903
[TBL] [Abstract][Full Text] [Related]
2. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.
Lv J; Guo L; Wang JH; Yan YZ; Zhang J; Wang YY; Yu Y; Huang YF; Zhao HP
World J Gastroenterol; 2019 Jan; 25(2):233-244. PubMed ID: 30670912
[TBL] [Abstract][Full Text] [Related]
3. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
4. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
6. Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma.
Lockwood WW; Thu KL; Lin L; Pikor LA; Chari R; Lam WL; Beer DG
Clin Cancer Res; 2012 Apr; 18(7):1936-46. PubMed ID: 22328562
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus.
Plum PS; Ulase D; Bollschweiler E; Chon SH; Berlth F; Zander T; Alakus H; Hölscher AH; Bruns CJ; Schallenberg S; Quaas A; Loeser H
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1731-1739. PubMed ID: 29974234
[TBL] [Abstract][Full Text] [Related]
8. TGM2: a cell surface marker in esophageal adenocarcinomas.
Leicht DT; Kausar T; Wang Z; Ferrer-Torres D; Wang TD; Thomas DG; Lin J; Chang AC; Lin L; Beer DG
J Thorac Oncol; 2014 Jun; 9(6):872-81. PubMed ID: 24828664
[TBL] [Abstract][Full Text] [Related]
9. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma.
Babar M; Ryan AW; Anderson LA; Segurado R; Turner G; Murray LJ; Murphy SJ; Johnston BT; Comber H; Reynolds JV; McManus R
Am J Gastroenterol; 2012 Sep; 107(9):1331-41. PubMed ID: 22664470
[TBL] [Abstract][Full Text] [Related]
10. Loss of FGL1 induces epithelial‑mesenchymal transition and angiogenesis in LKB1 mutant lung adenocarcinoma.
Bie F; Wang G; Qu X; Wang Y; Huang C; Wang Y; Du J
Int J Oncol; 2019 Sep; 55(3):697-707. PubMed ID: 31322182
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic liver kinase B1 promotes the growth of human lung adenocarcinoma by enhancing autophagy.
Liu M; Jiang L; Fu X; Wang W; Ma J; Tian T; Nan K; Liang X
Cancer Sci; 2018 Oct; 109(10):3055-3067. PubMed ID: 30033530
[TBL] [Abstract][Full Text] [Related]
12. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of LKB1 suppresses Stat3 activity to promote the proliferation of esophageal carcinoma cells.
Wang YQ; Dai WM; Chu XY; Yang B; Zhao M; Sun Y
Mol Med Rep; 2014 Jun; 9(6):2400-4. PubMed ID: 24676538
[TBL] [Abstract][Full Text] [Related]
14. DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma.
Whorton J; Sureban SM; May R; Qu D; Lightfoot SA; Madhoun M; Johnson M; Tierney WM; Maple JT; Vega KJ; Houchen CW
Dig Dis Sci; 2015 Feb; 60(2):509-13. PubMed ID: 25283374
[TBL] [Abstract][Full Text] [Related]
15. Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus.
Grady WM; Yu M
Dig Dis Sci; 2018 Aug; 63(8):2059-2069. PubMed ID: 29766388
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma.
Izzo JG; Wu TT; Wu X; Ensor J; Luthra R; Pan J; Correa A; Swisher SG; Chao CK; Hittelman WN; Ajani JA
J Clin Oncol; 2007 Feb; 25(6):698-707. PubMed ID: 17308274
[TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma.
Sun X; Martin RCG; Zheng Q; Farmer R; Pandit H; Li X; Jacob K; Suo J; Li Y
Cell Oncol (Dordr); 2018 Dec; 41(6):651-662. PubMed ID: 30116994
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa.
von Rahden BH; Kircher S; Kafka M; Stuermer L; Reiber C; Gattenlöhner S; Germer CT; Grimm M
Cancer Biomark; 2010; 7(6):285-94. PubMed ID: 21694467
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers.
Bobryshev YV; Orekhov AN; Chistiakov DA
Curr Pharm Des; 2015; 21(23):3402-16. PubMed ID: 25758856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
